We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Automated Hematology Analyzer Enumerates Peripheral Blood Stem Cells

By LabMedica International staff writers
Posted on 15 Jan 2014
The number of infused cluster of differentiation CD34+ cells, which are normally found in the umbilical cord and bone marrow as hematopoietic cells, is crucial to the success of peripheral blood stem-cell transplantation (PBSCT). More...


Although the ability to count CD34+ cells currently depends solely on flow cytometric analysis, the complexity of the procedure and cost of reagents, including monoclonal antibodies, are major disadvantages, which can be overcome using an automated hematology analyzer.

Scientists at the National Cancer Center Hospital (Tokyo, Japan) have introduced a novel method based on hemolysis and chemical staining, followed by flow cytometry-based optical detection, and conducted using an automated hematology analyzer. Cells expressing the CD34+ and hematopoietic progenitor cells (HPCs) were compared in 76 granulocyte colony-stimulating factor (G-CSF)-mobilized blood or apheresis samples taken from 18 healthy donors and 6 patients undergoing autologous PBSCT.

The newly launched XN-series model automated hematology analyzer (Sysmex Corporation; Kobe, Japan) was used to measure the HPCs. The XN-series model is equipped with a white precursor cell (WPC) channel to detect immature cells, such as myeloblasts and abnormal lymphocytes. The measuring principle of this channel utilizes the optical detection system and general flow cytometry. In this channel, two reagents are used: the lysis reagent containing a polyoxyethylene nonionic surfactant and the stain reagent containing a polymethine dye. CD34+ cells were isolated using MACS magnetic cell separation kits (Miltenyi Biotec; Bergisch Gladbach, Germany).

The investigators found a strong correlation between the numbers of HPCs and CD34+ cells. The expected total number of HPCs in the final products, which was estimated from HPCs in preapheresis peripheral blood (PB) or midapheresis products, also correlated well with the total number of CD34+ cells in the final products. The change in HPCs in PB closely resembled that of CD34+ cells during mobilization. Studies using immunomagnetic beads suggested that the majority of CD34+ cells existed in HPCs, and vice versa.

The authors concluded that their novel HPC enumeration method can be carried out without using monoclonal antibodies on an XN-series automated hematology analyzer. The final amount of collected CD34+ cells may be predicted from the total number of HPCs in the final products, as well as from preapheresis PB and intermediate products during apheresis. HPCs may also be a good indicator for the optimal timing of peripheral blood ste- cell collection. The study was published on December 27, 2013, in the International Journal of Laboratory Hematology.

Related Links:

National Cancer Center Hospital
Sysmex Corporation
Miltenyi Biotec



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Immunoassay Analyzer
Procise DX
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.